What were the competitive allegations in the Biogen kickback case?
The complaint alleged Biogen scheduled its own speaker events to coincide with rival Gilenya's launch to block doctors from attending, and targeted the roughly 1,200 physicians responsible for about 60% of MS prescriptions.
The complaint framed the payments as a strategy to defend Biogen's MS franchise. According to Pharmaceutical Technology, the whistleblower alleged Biogen tried to suppress sales of Novartis's Gilenya, the first oral MS drug, including by scheduling its own speaker events to coincide with Gilenya launch events so physicians could not attend.
The lawsuit described goals of preserving the eroding market share of Avonex, rebuilding Tysabri after safety concerns and ensuring Tecfidera's commercial success, and alleged Biogen targeted the roughly 1,200 doctors responsible for about 60% of MS prescriptions. These remain allegations; Biogen settled without admitting them. The case is frequently cited as a sign of heightened enforcement scrutiny of pharmaceutical speaker programmes.